I think we have two issues—or at least two—with that.
During the course of the categorization process, endocrine disruption and neurotoxicity were not human end points that were mandatory for evaluation in that process, but if there was data available on those points, it was considered during that process. If there was no data with respect to those end points, the government did not invoke some of the other provisions of the act, such as paragraph 71(1)(c), to require that either the information be provided or tests be performed. In that sense, with respect to the existing substances portion of CEPA and the CMP process, the evaluations that went forward left out neurotoxicity and endocrine disruption.
The same problem essentially applies in the context of new substances under section 80 and subsequent sections. There again, the opportunity to request that information is available to the government, but it often is not invoked, in part because of the language that appears not only in section 71, but also in sections 84 and 85—